Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Alberto PavanLorenzo CalvettiAlessandro Dal MasoIlaria AttiliPaola Del BiancoGiulia PaselloValentina GuarneriGiuseppe AprilePierFranco ConteLaura BonannoPublished in: The oncologist (2019)
This study was designed to investigate the role of blood biomarkers in predicting the occurrence of immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer receiving immunotherapy. The results of the study suggest a potential predictive role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as markers for irAE development in this category of patients. These data provide rationale for an easy and feasible application to be validated in clinical practice.
Keyphrases
- advanced non small cell lung cancer
- peripheral blood
- epidermal growth factor receptor
- clinical practice
- end stage renal disease
- chronic kidney disease
- risk assessment
- ejection fraction
- clinical trial
- oxidative stress
- prognostic factors
- machine learning
- electronic health record
- artificial intelligence
- tyrosine kinase
- patient reported